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Abstract
To develop an effective therapeutic strategy for cardiac regeneration using bone marrow mesenchymal stem cells (BM-
MSCs), the primary mouse BM-MSCs (1st BM-MSCs) and 5th passage BM-MSCs from b-galactosidase transgenic mice were
respectively intramyocardially transplanted into the acute myocardial infarction (AMI) model of wild type mice. At the 6th
week, animals/tissues from the 1st BM-MSCs group, the 5th passage BM-MSCs group, control group were examined. Our
results revealed that, compared to the 5th passage BM-MSCs, the 1st BM-MSCs had better therapeutic effects in the mouse
MI model. The 1st BM-MSCs maintained greater differentiation potentials towards cardiomocytes or vascular endothelial
cells in vitro. This is indicated by higher expressions of cardiomyocyte and vascular endothelial cell mature markers in vitro.
Furthermore, we identified that 24 proteins were down-regulated and 3 proteins were up-regulated in the 5th BM-MSCs in
comparison to the 1st BM-MSCs, using mass spectrometry following two-dimensional electrophoresis. Our data suggest that
transplantation of the 1st BM-MSCs may be an effective therapeutic strategy for cardiac tissue regeneration following AMI,
and altered protein expression profiles between the 1st BM-MSCs and 5th passage BM-MSCs may account for the difference
in their maintenance of stemness and their therapeutic effects following AMI.
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Introduction
Acute myocardial infarction (AMI), a main presentation of
ischemic heart disease, is one leading cause of death globally.
Although pharmacologic intervention and coronary artery bypass
grafting, which can restore the blood flow (reperfusion), keep
viable myocardium working, these approaches cannot rescue
dying myocardium or restore normal cardiac functions. Moreover,
new therapeutic approaches are needed for patients under critical
conditions suffering from small vessel diffuse lesions, who are
unable to withstand coronary angioplasty and for whom
medication is not effective. Therefore, it is imperative to develop
an effective therapeutic approach to regenerating myocardium
and restoring its normal contractile-relaxant function following
AMI. For a long time, it was commonly accepted that
cardiomyocytes, as terminally differentiated cell type, could not
be regenerated. Recently, accumulated evidence indicates that
cardiac muscles can be regenerated or repaired via a variety of
ways including stem cell technology [1].
To use stem cell technology for the treatment of AMI has been
one of the hot areas in cardiovascular research. BM-MSCs are
readily obtainable, safe, ethical, and an easy handling resource for
tissue transplantation with a high proliferation/differentiation
potential. It is low risk for immunorejection and pathogen
transmission. It also has a stable genetic background, so that has
been used as seeding cells in tissue engineering and stem cell
therapy [2,3,4,5,6]. BM-MSCs are primary seeding cells of heart
transplantation used for the treatment of AMI. Accumulated
evidence indicates that the transplantation of BM-MSCs can
effectively prevent ventricular remodeling, improve cardiac
performance, and ameliorate the outcome of ST-elevated AMI
[7,8,9,10,11,12].
Passaging in vitro has been a conventional approach to obtaining
a large number of BM-MSCs as required by transplantation.
However, during the sub-culture processing, BM-MSCs gradually
lose their differentiation potency towards cardiomyocytes and
vascular endothelial cells, and this is likely to result in less
satisfactory improvement in cardiac performance [13]. Previous
studies suggest that biological properties of BM-MSCs are not
everlasting features and their proliferation and differentiation
properties decline along with passaging process [13,14]. How to
obtain sufficient number of seeding cells, with a good quality of
stem cell biological properties for transplantation, remains the
center of stem cell therapy research.
Although therapy based on BM-MSCs has been gradually
introduced into clinics [15], their basic biological characteristics
remain largely unknown. It is generally accepted that BM-MSCs
are a highly adhesive fibroblast-like cell type. Our previous results
[16] jointly with data from others [17] indicate the existence of a
population of non-adherent, small, round cells, with self-renewal
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and multilineage differentiation potential in adult bone marrow,
and those cells are capable of forming CFU-Fs in vitro. Accordingly
we have developed the ‘‘Pour-off’’ method to amplify the 1st BM-
MSC.
It has been suggested that bone marrow milieu can preserve
stem cell properties of BM-MSCs [18]. Main marrow components
including hematopoietic cell population are present in primary
culture of BM-MSCs, but those components are missing when
BM-MSCs undergo repeat passaging on tissue culture plastic. This
change accounts for major differences between primary BM-
MSCs and repeat passage BM-MSCs in terms of culture
conditions. It is likely that hematopoietic cells maintain the self-
renewal and differentiation potency of the 1st BM-MSCs by
releasing cytokines and growth factors. Therefore, depletion of
hematopoietic cells may result in decline of differentiation potency
of repeat passage BM-MSCs towards cardiomyocytes and vascular
endothelial cells. Presumably the ‘‘Pour-off’’ method not only can
ensure to prepare sufficient numbers of BM-MSCs for the
transplantation, but also can help to retain differentiation potency
of BM-MSCs, possibly through the actions of hematopoietic cells,
which are present in conditioned culture media. Therefore, we
hypothesized that: i) the 1st BM-MSCs amplified using the ‘‘Pour-
off’’ method would be superior to repeat passage BM-MSCs in
terms of the potency of proliferation and differentiation, and
paracrine effects, and ii) the transplantation of the 1st BM-MSCs
would be superior to that of repeat passage BM-MSCs in terms of
therapeutic effectiveness for AMI. In the present study, the
primary mouse BM-MSCs (1st BM-MSCs) and 5th passage BM-
MSCs from b-galactosidase transgenic mice were respectively
intramyocardially transplanted into AMI model of wild type mice.
At the 6th week, animals/tissues from the 1st BM-MSCs group, the
5th passage BM-MSCs group, control group were examined. To
investigate the potential mechanisms underlying the differential
therapeutic effects, we utilized in vitro culture systems and cellular/
molecular and proteomics techniques. We examined the profiles of
proliferation, apoptosis, and differentiation potentials towards
cardiomyocytes and vascular endothelial cells of the 1st or the 5th
passage BM-MSCs, and expressions of gene markers for
pluripotent stem cells or tissue committed stem cells expressed
by the two types of cells, and identified protein expression profiles
between the 1st BM-MSCs and the 5th passage BM-MSCs.
Materials and Methods
Adult C57BL/6J and b-gal transgenic mice weighing 2062 g
were obtained from the Jackson Laboratory. The use of animals in
this study was approved by the Institutional Animal Care and Use
Committee of Nanjing Medical University (Approval ID 2008-
00318).
BM-MSC cultures and harvesting
b-gal transgene mice were killed by cervical dislocation. Total
BMCs were flushed out of tibias and femurs. After washing, cells
were centrifuged, and resuspended in 10 ml normal culture
medium consisting of a-MEM containing 10% (v/v) fetal bovine
serum, 2 mM L-Glutamine and 50 mg/ml Ascorbic acid, to a final
concentration of 107 viable cells in 10 cm petri dishes and kept in a
humidified 5% CO2 incubator at 37uC. ‘‘Pour-off’’ cultures were
performed as previously described [16]. Briefly, after total BMCs
were kept in a humidified 5% CO2 incubator at 37uC for 24 h in
the absence or presence of 1028 M 1,25-dihydroxyvitamin D3,
non-adherent cells (NA) were resuspended into a new 10 cm petri
dish and repeated 4 times again in this way. Fresh medium was
added to all the dishes. Adherent BMC cells obtained from either
way were termed as the 1st BM-MSCs. Subsequently, confluent 1st
BM-MSCs by ‘‘Pouring-off’’ were trypsined and sub-cultured. The
1st BM-MSCs and passage 5 BM-MSCs were used in the study.
Lacz staining for b-galactosidase activity
Pre-embedding LacZ staining was performed following a
modified version of a previously described method [19].
Myocardial infarction model and BM-MSCs
transplantation
When the Left ventricular anterior transmural MI of 45 mice
was established by permanent ligation of the ramus descendens
anterior arteriae coronariae sinistrae with silk ligature using
C57BL/6J wild type mice. The 1st BM-MSCs group (MI+1st
MSCs group) and the 5th BM-MSCs group (MI+5th BM-MSCs
group) were separately injected into the border zone surrounding
the infarct anteriorly and laterally (total 5.06106 cells in 0.05 ml
a-MEM) with a 31-gauge needle after the ligation of the left
anterior descending artery. Control groups including 15 mice were
established by injection of the same volume of a-MEM into the
infarcted heart (MI group). A sham group was also included in
which the surgery was performed but without ligation of the
coronary artery (Sham group). MI group and Sham group were
detected electrocardiographs using RM6240 system (Chengdu
Instrument Company, Chengdu, China) to determine MI models.
RNA isolation and real-time RT-PCR
RNA was isolated from MSCs using Trizol reagent (Invitrogen
Inc., Carlsbad, CA, USA) according to the manufacturer’s
protocol. Sample mRNA levels were quantified by real-time
RT-PCR as previously described [20]. The PCR primers are
shown in Table 1.
Immunohistochemiscal staining and
immunofluorescence labeling procedures
For immunohistochenmistry, the mice were anesthetized with
3% pentobarbital sodium (40 mg/kg) after 6 weeks following
transplantation. Myocardial specimens were perfused with 100 ml
normal sodium and then perfused and fixed with PLP solution.
The 0.5 cm transverse sections of the short axis of the left
ventricles below the artery ligation site were removed and
embedded in paraffin and cut into 5-mm sections. Serial paraffin
sections were deparaffinized, dehydrated, and, for antigen
retrieval, steamed for 20 minutes in PBS (0.01 mM pH 7.4)
followed by blocking of endogenous peroxidase (3% H2O2) and
preincubation with serum. Primary antibodies against b-galacto-
sidase (Dako Cytomation, Denmark), vascular endothelial growth
factor (VEGF) (R&D, America), platelet endothelial cell adherence
molecular (PECAM) (Santa Cruz Biotechnology, America),
proliferating cell nuclear antigen (PCNA) (Dako Cytomation,
Denmark), Troponin I (Santa Cruz Biotechnology) and Desmin
(Thermo, America) were used. After washing steps, the sections
were incubated with secondary antibody (biotinylated IgG;
Sigma), washed again, and processed using the Vectastain ABC-
HRP kit (Vector Laboratories, Inc.). The sections were then
counterstained with Hematoxylin and mounted with Biomount
medium. For immunofluorescence labeling procedures, corre-
sponding affinity-purified Rhodamine (TRITC), Texas Red
(TXRD) or FITC-conjugated secondary antibody (Santa Cruz
Biotechnology) were used. Nuclei were labeled by DAPI (Sigma)
and mounted with medium which prevents quenching of
fluorescence (Vector Laboratories, Inc.). After immunohistochem-
ical and immunofluorescence staining, images of the infarct border
Stem Cell Therapy of Myocardial Infarction
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21005
zone at the posterior left ventricles from a single section were
digitally recorded using a rectangular template and three different
fields at6200 magnification. All images were taken with a Sony
digital camera, and processed using Northern Eclipse image
analysis software, version 5.0 (Empix Imaging, Inc., Mississauga,
Canada). The immunopositive area or positive cell numbers from
each section were averaged and expressed as the ultimate positive
area or the number of positive cells per field.
TUNEL Staining
Dewaxed paraffin sections were stained with an In Situ Cell
Death Detection Kit (Roche Diagnostics Corp.) using a previously
described protocol [21].
Fibrosis quantification and measurement of infarct zone
wall thickness
Total collagen was detected in paraffin sections using a method
previously described [20]. Six anterolateral sections from each
heart were evaluated in their entirety and quantified. The results
were expressed as a percentage of each ventricular section. For
measurement of infarct zone wall thickness on each section, two
measurements were obtained in the peri-infarct region, one on
each side of the infarct and averaged. Measurements were
obtained in a group-blinded manner [22].
Echocardiography
Echocardiography was done after ligation of the left anterior
descending artery and immediate transplantation of BM-MSCs 1
and 6 weeks later with a 7.5-MHz high-frequency liner phased-
array transducer (GE vivid7). Animals were lightly sedated with
ketamine (50 mg/kg) for each echocardiogram. Measurements
were made by two independent observers unaware of the
treatment condition, offline with Philips Qlabz. For analysis of
left ventricular function, left ventricular internal diameter at end-
diastole (LVIDd), left ventricular internal diameter at end-systole
(LVIDs), left ventricular end-diastolic volume(LVEDV) and left
ventricular end-systole volume (LVESV) were measured at the
anterior wall, from the short-axis view, just below the level of the
papillary muscle. The shortening fraction was calculated as
(LVEDD-LVESD) 100%/LVEDD, and ejection fraction was
measured as (LVEDV-LVESV) 100%/LVEDV.
Western Blot
Samples of the infarct border zone of the posterior left ventricles
from 0.5 cm transverse sections of the short axis below the ligation
site were dissected and immediately placed into a lysis buffer
containing a cocktail of proteinase inhibitors for protein
extraction. Protein extracts from each group were boiled for
5 min in the sample buffer, fractionated by SDS gel electropho-
resis and transferred to nitrocellulose membranes. The membrane
was blocked for 2 h at 37uC with 5% non-fat dry milk in PBS/
Tween 20. The blots were incubated overnight at 4uC with
antibodies against Akt (Santa Cruz Biotechnology), phospho-Akt
(pAkt) (Santa Cruz Biotechnology), STAT5 (Sigma), phospho-
STAT5 (pSTAT5) (Sigma), Pro-Caspase3 (Santa Cruz Biotech-
nology), Activate-Caspase3 (Cell Signaling Technology) and b-
tubulin (Santa Cruz Biotechnology). This was followed by
incubation for 1 h with HRP-conjugated secondary antibody.
Immunoreactive bands were visualized using enhanced chemilu-
minescence reagent treatment and exposure to hyperfilm-ECL.
The intensity of the bands was measured using Image J version
1.29.
2-D Electrophoresis and Mass Spectrometry
Immobilized pH gradient strips (GE Healthcare, San Francisco,
CA) were rehydrated using 120 mg of cell total proteins from BM-
MSCs. After isoelectric focusing, the strips were equilibrated, run
Table 1. Sequences of primers employed for Real time RT-
PCR.
Name S/AS Sequence Tm(6C) bp
Desmin S 59-GTGGATGCAGCCACTCTAGC -39 60 218
AS 59-TTAGCCGCGATGGTCTCATAC-39
Troponin I S 59-TCTGCCAACTACCGAGCCTAT-39 60 135
AS 59-CTCTTCTGCCTCTCGTTCCAT-39
MHC-b S 59-TTCATCCGAATCCATTTTGGGG-39 60 194
AS 59-GCATAATCGTAGGGGTTGTTGG-39
VEGF S 59-GGAGATCCTTCGAGGAGCACTT-39 55 129
AS 59-GGCGATTTAGCAGCAGATATAAGAA-39
FLT-1 S 59-GAGGAGGATGAGGGTGTCTATAGGT-39 55 116
AS 59-GTGATCAGCTCCAGGTTTGACTT-39
KDR S 59-GCCCTGCTGTGGTCTCACTAC-39 55 97
AS 59-CAAAGCATTGCCCATTCGAT-39
Oct4 S 59-CGCCCGCATACGAGTTCT-39 51 188
AS 59-CTTCTCCAACTTCACGGCATT-39
CXCR4 S 59-GACGGACAAGTACCGGCTGC-39 51 480
AS 59-GACAGCTTAGAGATGATGAT-39
MET-R S 59-CGCGTCGACTTATTCATGG-39 51 363
AS 59-CACACATTGATTGTGGCACC-39
LIF-R S 59-CCAAGGACGGAACCAGTAGCA-39 53 153
AS 59-GGAGAAATGAGGCGAGTCAA-39
Dppa3 S 59-GCAGTCTACGGAACCGCATT-39 50 71
AS 59-TTGAACTTCCCTCCGGATTTT-39
Nanog S 59-CGTTCCCAGAATTCGATGCTT-39 50 106
AS 59-TTTTCAGAAATCCCTTCCCTCG-39
Rex-1 S 59-AGATGGCTTCCCTGACGGATA-39 49 104
AS 59-CCTCCAAGCTTTCGAAGGATTT-39
RIF-1 S 59-TTTCCTTGCCCTCTATGA-39 51 146
AS 59-AACAATTTCTCCCAATAGCTT-39
Csx S 59-AGACCCTCGGGCGGATAAA-39 48 155
AS 59-GCCGCTCCAGCTCGTAGACCT-39
GATA-4 S 59-TCCAGTGCTGTCTGCTCTAAGC-39 50 266
AS 59-TGGCCTGCGATGTCTGAGT-39
VE-cadherin S 59-TTCAAGCTGCCAGAAAACCA-39 49 68
AS 59-GAGCCTTGTCAGGGTCTTTGG-39
MT1-MMP S 59-GGACAGCGAGTACCCTA-39 50 113
AS 59-ATTTGTTTCCCTTGTAGAAGT-39
MMP2 S 59-ATCTTTGCAGGAGACAAGTTC-39 51 114
AS 59-GGCATCCAGGTTATCAG-39
MMP9 S 59-TCTACAGAGTCTTTGAGTCCG-39 53 134
AS 59-GGGCTTCCTCTATGATTCAG-39
GAPDH S 59-CATTTCACTCAAGGTTGTCAGC-39 55 346
AS 59-ATCATACTTGGCAGGTTTCTCC-39
Real-time RT-PCR primers used with their name, orientation (S, sense; AS,
antisense), sequence, annealing temperature (Tm), and length of amplicon (bp).
doi:10.1371/journal.pone.0021005.t001
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in the Ettan DALT-6 electrophoresis system, and visualized by
silver staining, as described previously [23].
The stained gels were scanned, and the Image Master 2D
Platinum Software (Version 6.0; GE Healthcare, Swiss Institute of
Bioinformatics) was used for spot detection, quantification, and
comparative and statistical analyses, as previously described [23].
In each experiment, protein expression in the 1st BM-MSCs and
the 5th BM-MSCs were compared at baseline. The values from
each group were pooled for the calculation of the means and their
respective standard deviations, and independent t-test was
performed to determine the significance of the differences between
protein expression in the 1st BM-MSCs and the 5th BM-MSCs.
Values of P,0.05 were considered as statistically significant.
Differential silver-stained protein spots were excised, dehydrat-
ed in acetonitrile, and dried at room temperature. The proteins
were reduced with 10 mM DTT and 25 mM NH4HCO3 at 56uC
for 1 h and alkylated in the dark with 55 mM iodoacetamide and
25 mM NH4HCO3 at room temperature for 45 min in situ. The
gel pieces were then thoroughly washed with 25 mM NH4HCO3,
50% acetonitrile, and 100% acetonitrile in succession and were
completely dried in a Speedvac. The dried gel pieces were
reswollen with 2–3 ml of trypsin solution (trypsin at a concentra-
tion of 10 ng/ml in 25 mM NH4HCO3). After incubation at 4uC
for 30 min, the excess liquid was discarded, and the gel plugs were
incubated at 37uC for 12 h. Finally, 0.1% trifluoroacetic acid was
added to stop the digestion reaction. The extracted peptide
mixture was then analyzed by MALDI-TOF (Biflex, Bruker
Daltonics).
Database Searches: Each acquired mass spectrum (m/z range,
700–4000; resolution, 15 000–20 000) was processed using the
software Flex Analysis version 2.0 (Bruker Daltonics). The tryptic
autodigestion ion peaks (842.51 and 1045.56 Da,) were used as
internal standards to validate the external calibration procedure.
Matrix and/or autoproteolytic trypsin fragments or known
contaminants were removed. The resulting peptide mass lists
were first used to search the Swiss-Prot 48.7 database (release 10/
09/05; 204 086 sequences; 74,182,688 residues) for Homo sapiens
(13,344 sequences) by using Mascot (version 2.1.03) in the
Figure 1. Establishment of acute myocardium infarction mouse model. (A) Representative graphs of the overall hearts from sham operation
(left panel) and from the permanent ligation of the ramus descendens anterior arteriae coronariae sinistrae with silk ligature (MI, right panel), red,
black and blue arrow indicate for MI occurred in anterior wall, lateral wall and posterior wall of left ventricle, respectively. (B) Representative
micrographs of cross sections of ventricles stained with H & E. (C) Representatice micrographs of sections of left ventricles stained with H & E. Black
arrows indicate sarcoplasmic condensation occurred in MI areas. Scale bars in A, B and C represent 4000, 800 and 25 mm, respectively. (D)
Representative electrocardiographs. The arrow noted that ST segment was elevated in MI animals. Each mini-panel standed for 0.025 s.
doi:10.1371/journal.pone.0021005.g001
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automated mode. In cases where we were unable to obtain a
confident result, the mass lists were used to further search the
TrEMBL 31.7 database (release 10/09/05; 2,506,886 sequences;
805,901,253 residues) for Homo sapiens (58,416 sequences), which
is a supplement to the Swiss-Prot database. The search conditions
used were as described in previous work [23]. The peptide mass
was compared with the theoretical peptide masses of all available
proteins from a species. The search conditions used were as
follows: 100 ppm for external calibration, one missed cleavage
allowed, and modification of cysteines by iodoacetamide, methi-
onine oxidation, and N-terminal pyroglutamylation as variable
modifications. The minimal requirement for an identity assign-
ment was 4 matching peptides, and we only considered mouse
proteins. The algorithm used for determining the probability of a
false-positive match with a given MS spectrum is described
elsewhere [24].
Statistical analysis
Statistical analysis was performed with SPSS for Windows
(version 13.0). All datas were described as mean 6 S.E.M of
determinations in five animals of each group. To analyze the data
statistically, we performed Student’s t-test and one way ANOVA.
Values of P,0.05 were considered statistically significant.
Results
Establishment of acute myocardium infarction mouse
model
An acute myocardium infarction model was established using
57BL/6J mice in reference to a protocol described previously [25].
MI areas were visualized in the anterior wall, lateral wall or
posterior wall of the left ventricle respectively as early as 24 hours
following the ligation of the left coronary artery (Figure 1A). The
left ventricle MI walls became much thinner in comparison to
sham controls. Moreover, at the acute stage of injury type
MI,inflammatory cell infiltration and representative pathological
characteristics of sarcoplasmic condensation were observed
(Figures 1B and C). Furthermore, electrocardiographic analysis
showed an elevated ST segment in MI mice (Figure 1D).
Preparation and characterization of seeding cells for the
transplantation
We have showed previously that not only total BMCs can give
rise to colony-forming units-fibroblasts (CFU-fs), but also the non-
adherent fraction (‘Pour-off’ NA-BMCs), indicating the presence
of ‘non-adherent’ mesenchymal stem cells (NA-MSCs) in rat bone
marrow [16]. First of all, in this study, we examined the clonogenic
ability of mouse BMCs using the ‘Pour-off’ method. In agreement
with the results obtained from the rat cells, our results showed that
both total mouse BMCs and NA-BMCs can give rise to CFU-fs.
Also the efficiency of CFU-fs in PO2, PO3, PO4, and PO5
increased 14%, 84%, 161% and 172%, respectively, following the
treatment of cells with 1, 25-dihydroxyvitamin D3 (10
28 M) in
mouse BMCs (Figures 2A and B). These results suggest that using
of the ‘‘Pour-off’’ method on cultures can maximize the quantity of
BM-MSCs, which can be used as seeding cells for tissue
transplantations, from limited numbers of adult mouse BMCs.
Pooled BM-MSCs from the primary total and PO1–5 BMC
cultures were subcultured for 5 passages. The b-gal transgenic
mouse-derived BM-MSCs from both the 1st pour off cultures and
the 5th passaged cultures, which were positive for b-gal (Figures 2C)
as demonstrated by LacZ cytochemical staining, were used as
donor cells for the transplantation.
To compare potential differences between the 1st and passaged
BM-MSCs, the b-gal transgenic mouse-derived BM-MSCs from
the 1st pour-off cultures (the 1st BM-MSC) and the 5th passaged
cultures (the 5th BM-MSC) were further characterized by
comparison of expression levels of markers of pluripotent stem
cells, matrix metalloproteinases (MMPs), protein expression
profile, and differentiation potential into cardiomyocytes or
vascular endothelial cells. Our results showed that mRNA levels
of markers for pluripotent stem cells (OCT-4, CXCR4, LIF-R,
Dppa3, Nanog, MET-R, Rex-1 and RIF-1) (Figures 2D–K), for
cardiac-committed stem cells (Csx and GATA-4) (Figures 2L, M)
or for vascular endothelial-committed stem cells (VE-Cadherin)
(Figures 2N) in the 1st BM-MSCs were significantly higher than
those in the 5th passage BM-MSCs. These results indicate that the
stemness maintenance of the 1st BM-MSCs is superior to that of
the 5th BM-MSCs. Our results also showed that mRNA levels of
MT1-MMP, MMP-2 and MMP-9 (Figures 2O–Q) in the 1st BM-
MSCs were higher than those in the 5th passage BM-MSCs. This
implies that migration properties of the 1st BM-MSCs may be
superior to that of the 5th BM-MSCs.
The comparison of protein expression profile was performed by
2-D electrophoresis (Figures 3A) and mass spectrometric analysis.
Our results showed that 27 protein spots were identified to be
differentially expressed by the 1st BM-MSCs for at least 5 times in
comparison to the 5th BM-MSCs. Among those proteins, 24
proteins were down-regulated and 3 proteins were up-regulated in
the 5th BM-MSCs. Some proteins among them have been known
to be involved in regulating cellular functions of stem cells, which
include adhesion, homing, engraftment, angiogenesis, anti-apop-
tosis, protecting cells from oxidative stress, and modulating
inflammatory and immune responses (Table S1).
To compare differentiation potential into cardiomyocytes or
vascular endothelial cells between the 1st BM-MSCs and the 5th
BM-MSCs, 59-aza and VEGF were used for differentiation of BM-
MSC into cardiomyocytes and vascular endothelial cells, respec-
tively, and gene expressions of cardiomyocyte markers or vascular
Figure 2. Preparation and characterization of donor cells. (A) Representative methylene blue stained cultures from mouse total BM cells (total
BMC), the first pour-off (PO1) (that was, colonies from non-adherent supernatant cells in the first pour-off that became adherent and proliferated), the
second pour-off (PO2), the third pour-off (PO3), the fourth pour-off (PO4) and the fifth pour-off (PO5) in the absence (control, upper panel) and
presence of 1028 M 1,25(OH)2D3 (lower panel). The initial red arrow indicated that PO1 was derived from non-adherent supernatant cells of total
unmanipulated bone marrow and subsequent red arrows indicated that sequential pour-offs were derived from cultures of previous supernatant
cells. (B) The number of CFU-fs was quantitated in the pour-off cultures stained with methylene blue and was depicted as mean6s.e.m. of triplicate
determinations. (C) Micrographs of cells from the primary pour off cultures and 5th passaged cultures stained cytochemically for ß-gal activity. Scale
bar represents 25 mm. (D) OCT-4, (E) CXCR4, (F) LIF-R, (G) Dppa3, (H) Nanog, (I) MET-R, (J) Rex-1, (K) Rif-1, (L) Csx, (M) GATA-4, (N) VE-cadherin, (O) MT1-
MMP, (P) MMP2 and (Q) MMP9 mRNA levels were examined in BM-MSCs from the primary pour-off cultures (1st BM-MSCs) and the 5th passaged
cultures (5th BM-MSCs) by real-time RT-PCR. The mRNA levels were calculated as a ratio to the GAPDH mRNA level and expressed relative to levels of
the 1st BM-MSCs. Each value was the means6S.E.M. of 5 determinations. **, P,0.01; ***, P,0.001 compared with 1st BM-MSCs. ##, P,0.01; ###,
P,0.001 compared with control cultures.
doi:10.1371/journal.pone.0021005.g002
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endothelial cell markers were examined by real-time RT-PCR.
Results showed that mRNA levels of either immature cardiomy-
ocyte marker, desmin or mature cardiomyocyte markers, troponin
I and MHC-b in the 1st BM-MSCs were higher than those in the
5th BM-MSCs in the absence or presence of 59-azacytidine. Also
following the treatment of 59-azacytidine, mRNA levels of desmin
were downregulated while mRNA levels of troponin I were
upregulated either in the 1st BM-MSCs or in the 5th BM-MSCs,
and mRNA levels of MHC-b was upregulated in the 1st BM-
MSCs while they remained unchanged in the 5th passage BM-
MSCs (Figures 3B–D). mRNA levels of either VEGF or its
receptors, KDR and FLT-1, in the 1st BM-MSCs were higher
than those in the 5th BM-MSCs in the absence or presence of
VEGF. Following the treatment of VEGF, mRNA levels of VEGF
were upregulated, while mRNA levels of FLT-1 either in the 1st
BM-MSCs or in the 5th BM-MSCs remained unchanged. mRNA
levels of KDR remained unchanged in the 1st BM-MSCs while
they were upregulated in the 5th BM-MSCs (Figures 3E–G). These
results suggest that the 1st BM-MSCs have higher differentiation
potential into cardiomyocytes or vascular endothelial cells than the
5th BM-MSCs do.
Distribution of donor cells in MI areas and infarct border
zones following the transplantation
To trace the b-gal+ primary and the 5th BM-MSCs in recipient
hearts, we analyzed heart specimens after 6 weeks, following the
transplantation using LacZ histochemical staining and immuno-
histochemical staining for b-gal. Our results showed that no
LacZ+ staining was detected in the heart from either sham or MI
mice without the transplantation, whereas patch-like LacZ+
staining was detected at MI areas from both the MI+1st BM-
MSCs group and the MI+5th BM-MSCs group, but the area of
LacZ+ staining in the hearts from the MI+1st BM-MSCs group
was greater than that from the MI+5th BM-MSCs group
(Figures 4A). Moreover, as revealed by H.E. counter-staining,
diffusive LacZ+ cells were only seen in the hearts from either the
MI+1st BM-MSCs group or the MI+5th BM-MSCs group, and
numbers of LacZ+ cells in the hearts from the MI+1st BM-MSCs
group were greater than those from the MI+5th BM-MSCs group
(Figures 4B and C). In agreement with the LacZ staining results,
immuohistochemical staining revealed that b-gal+ cells were only
seen in the hearts from either the MI+1st BM-MSCs group or the
MI+5th BM-MSCs group, and that numbers of b-gal+ cells in the
hearts from the MI+1st BM-MSCs group were greater than those
from the MI+5th BM-MSCs group (Figures 4D and E).
Furthermore, as shown by histomorphometric analysis, area of
cells either positive for LacZ or b-gal in the hearts from the
MI+1st BM-MSCs group was greater than that from the MI+5th
BM-MSCs group, and notably the area of cells positive for b-gal
was greater than that of cells positive for LacZ (Figures 4F and
G), indicating that not all of the cells positive for b-gal had b-
galactosidase activity. These results suggested that properties of
cell survival and homing into MI area for the 1st BM-MSCs are
superior to those for the 5th BM-MSCs.
Differentiation capacity of donor cells towards
cardiomyocytes or neovasculature and vascular
endothelial cells in infarct border zones following the
transplantation
To assess differentiation capacity of donor cells towards
cardiomyocytes or neovasculature and vascular endothelial cells
in infarct border zones following the transplantation, double
immunofluorescence staining for b-gal and troponin I/desmin or
for b-gal and PECAM/VEGF were performed after 6 weeks
following the transplantation. Our results showed that double
positive areas b-gal and troponin I/desmin were only detected in
the MI+1st BM-MSCs group or the MI+5th BM-MSCs group, and
the percentage of those double positive areas in the MI+1st BM-
MSCs group was significantly higher than those in the MI+5th
BM-MSCs group (Figures 5A, B, E and F). These results indicate
that the differentiation capacity towards cardiomyocytes of the 1st
BM-MSCs, as donor seeding cells following MI, is greater than
that of the 5th BM-MSCs.
It was also found that areas of vasculature stained positive for
PECAM/VEGF in the MI group were greater than those in the
sham group. The transplantation of the 1st BM-MSCs or the 5th
BM-MSCs into MI models resulted in increased percentages of
areas of vasculature stained positive for VEGF/PECAM in infarct
border zones. Also, the percentage of those positive areas in the
MI+1st BM-MSCs group was significantly greater than those in
the MI+5th BM-MSCs group. Double positive areas for b-gal and
VEGF/PECAM were only detected in the MI+1st BM-MSCs
group or the MI+5th BM-MSCs group. The percentage of those
double positive areas in the MI+1st BM-MSCs group was
significantly greater than those in the MI+5th BM-MSCs group
(Figures 5C, D, G and H). These results indicate that: MI results in
neovasculature formation in MI areas and infarct border zones;
the transplantation of BM-MSCs can promote neovasculature
formation in the affected areas; the transplantation of the 1st BM-
MSCs has a greater effect on neovasculature formation than that
of the 5th BM-MSCs and differentiation capacity towards
vasculature tissue of the 1st BM-MSCs as donor seeding cells
following MI is greater than that of the 5th BM-MSCs.
Assessments of cell proliferation and apoptosis in the
myocardium following the transplantation of the 1st or
the 5th BM-MSCs into the MI models
To assess cell proliferation and apoptosis in the myocardium,
immunohistochemical staining for PCNA and TUNEL assay for
apoptotic nuclei in infarct border zones was performed after 6
weeks following the transplantation of the 1st or the 5th BM-MSCs
into the MI models. Our results showed that: i) PCNA-positive
cells were occasionally present in the myocardium and on the
periphery of heart vasculatures in the sham group and were
increased in MI areas and infarct border zones in the MI group;
the percentage of PCNA-positive cells in infarct border zones
either in the MI+1st BM-MSCs group or the MI+5th BM-MSCs
group was significantly greater than those in MI group; the
percentage of PCNA-positive cells in infarct border zones in the
Figure 3. Protein expression profile and differentiation of the primary and 5th passaged BM-MSCs toward cardiocytes and vascular
endothelial cells in vitro. (A) The representative images of silver stained 2-DE gel of the proteins from the primary pour-off cultures (upper panel,
1st BM-MSCs) and the 5th passaged cultures (low panel, 5th BM-MSCs). (B) Desmin, (C) Troponin I, (D) MHC-ß, (E) VEGF, (F) FLT-1 and (G) KDR mRNA
levels were examined in BM-MSCs from the primary pour-off cultures (1st BM-MSCs) and the 5th passaged cultures (5th BM-MSCs) induced by 59-
azacytidine (B–D) and VEGF (E–G) by real-time RT-PCR. The mRNA levels were calculated as a ratio to the GAPDH mRNA level and expressed relative to
levels of the 1st BM-MSCs. Each value was the means6S.E.M. of 5 determinations. **: P,0.01; ***: P,0.001 compared with the 1st BM-MSCs.
doi:10.1371/journal.pone.0021005.g003
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MI+1st BM-MSCs group was significantly greater than that in the
MI+5th BM-MSCs group (Figures 6A, and C). TUNEL assay
results showed that TUNEL-positive nuclei were occasionally
present in the myocardium in the sham group and were increased
in infarct border zones in the MI group; the percentage of
TUNEL-positive nuclei in infarct border zones either in the
MI+1st BM-MSCs group or the MI+5th BM-MSCs group was
reduced significantly compared to that in MI group; the
percentage of TUNEL-positive nuclei in infarct border zones in
the MI+1st BM-MSCs group was reduced significantly compared
to that in the MI+5th BM-MSCs group (Figures 6B and D). Those
results indicate that MI results in cell proliferation and apoptosis in
infarct border zones; the transplantation of BM-MSCs into MI
models enhanced cell proliferation and attenuated apoptosis in
infarct border zones; the 1st BM-MSCs has a more evident impact
on either stimulating cell proliferation or inhibiting cell apoptosis
in infarct border zones than the transplantation of the 5th BM-
MSCs.
Furthermore, to investigate possible mechanisms underlying
attenuated cell apopotsis in infarct border zones following
transplantations of BM-MSCs, we examined the expression of
Akt, phospho-Akt (pAkt), STAT5, phospho-STAT5 (pSTAT5),
pro-caspase 3 and active caspase 3 in lysate samples prepared from
infarct border zones, following the transplantations using Western
blotting. Our results showed that: there is no apparent difference
in levels of either Akt or STAT5 in lysate samples between the
sham group and the MI group and either pAkt or pSTAT5 was
undetectable in the two groups; levels of both pro-caspase 3 and
active caspase 3 were upregulated in lysate samples from the MI
group; interestingly, levels of either Akt or pAkt was upregulated in
lysate samples from both the MI+1st BM-MSCs group and the
MI+5th BM-MSCs group; pSTAT5 became detectable while
STAT5 levels remained unchanged in both the MI+1st BM-MSCs
group and the MI+5th BM-MSCs group; Levels of both pro-
caspase 3 and active caspase 3 were downregulated in both the
MI+1st BM-MSCs group and the MI+5th BM-MSCs group; levels
of Akt, pAkt, or pSTAT5 in lysate samples from the MI+1st BM-
MSCs group were significantly higher than those in the MI+5th
BM-MSCs group and levels of both pro-caspase 3 and active
caspase 3 were in lysate samples from the MI+1st BM-MSCs group
were significantly lower than those in the MI+5th BM-MSCs group
(Figures 6E–K).
Assessment of cardiac functions following the
transplantation of the 1st or the 5th BM-MSCs into MI
models
By histochemical staining for total collagen and histomorpho-
metric analysis at the 6th week after MI revealed that the
percentage of positive areas for total collagen in the left ventricle
wall in the MI group was greater than that in the sham group, the
transplantation of BM-MSCs into MI models resulted in an
increased thickness of the infarct border zone ventricular wall and
decreased positive areas for total collagen. Also the thickness of the
infarct border zone ventricular wall in the MI+1th BM-MSCs
group increased more significantly and positive areas for total
collagen decreased more significantly in comparison to the MI+5st
BM-MSCs group (Figures 7A–C).
To assess cardiac functions, echocardiographic analyses were
performed after 1 or 6 weeks following the transplantation.
LVIDd, LVIDs, LVEDV and LVESV were increased significantly
while LVFS and LVEF were decreased significantly in the MI
group compared to the sham controls. After 1 week following the
transplantation, LVIDd, LVIDs, LVEDV and LVESV were
decreased while LVFS and LVEF remained unchanged in the
MI+1st BM-MSCs compared to the MI group, in contrast, these
parameters were not altered in the MI+5th BM-MSCs group. After
6 weeks following the transplantation, LVIDd, LVIDs, LVEDV
and LVESV were decreased, whereas LVFS and LVEF were
increased in both the MI+1st BM-MSCs and the MI+5th BM-
MSCs groups compared to the MI group. The alterations of these
parameters were more dramatic in the MI+1st BM-MSCs group
compared to the MI+5th BM-MSCs group (Figures 7D–J). These
results indicate that the transplantation of either the 1st BM-MSCs
or the 5th BM-MSCs can increase the thickness of the infarct
border zone ventricular wall, alleviate myocardial fibrosis and
improve left ventricular functions. Also, the transplantation of the
1st BM-MSCs has a better therapeutic effect as a means for MI
than the transplantation of the repeated passage BM-MSCs.
Discussion
The transplantation of stem cells is believed to be a promising
approach to treatment of ischemic heart diseases, which cannot be
cured by medication or surgical interventions. BM-MSCs are
highly self-renewable multipotent stem cells and have been widely
used in therapeutic transplantation and tissue engineering [2].
However, BM-MSCs are not immortal and their capacities of
proliferation and differentiation are known to be impaired through
the repeated passaging process in vitro [26]. Repeated passaging, a
conventional approach to amplify BM-MSCs for sufficient
numbers required for a successful transplantation, is known to
compromise the stem cell biological characteristics of BM-MSCs
[16]. Unsatisfactory therapeutic effect is likely to be attributable to
the utilization of repeated passaging BM-MSCs, which only have
an impaired regeneration capacity for either cardiac muscles or
vascular tissues, as seeding cells for heart transplantation following
acute MI. Therefore it is imperative to seek a population of BM-
MSCs which have fine stem cell biological characteristics, and can
be amplified extensively, for satisfactory therapeutic effect
following acute MI. BM-MSCs are generally regarded as a highly
adhesive fibroblast-like cell type. However, our previous results
[16], in agreement with other reports [17], have indicated the
existence of a population of non-adherent and round cells with
self-renewal and differentiation potency towards multiple tissues,
and these cells are also capable of forming CFU-Fs in vitro.
Accordingly, we have developed the ‘‘Pour-off’’ method to amplify
primary BM-MSC and have demonstrated that the treatment of
Figure 4. Distribution of donor cells in MI areas and infarct border zones following the transplantation. (A) Representative graphs of
left ventricles from sham, MI, MI with the transplantation with the 1st BM-MSCs (MI+1st BM-MSCs) or with the 5th BM-MSCs (MI+5th BM-MSCs) stained
histochemically for ß-Gal activity. Representative micrographs of (B) MI areas stained histochemically for ß-Gal activity and counterstained with H & E
and (C) infarct border zone stained histochemically for ß-Gal activity and counterstained with Hematoxylin. Representative micrographs of (D) MI
areas and (E) infarct border zone immunostained for ß-Gal and counterstained with Hematoxylin. (F) Representative micrographs of infarct border
zone immunostained for VEGF. (G) Representative micrographs of infarct border zone immunostained for PECAM. Scale bars in A–G represent 4000,
50, 25, 25, 25, 50 and 25 mm, respectively. (H) LacZ positive areas, (I) ß-Gal immunopositive areas, (J) VEGF immunopositive areas and (K) PECAM
immunopositive areas were quantitated by computer-assist image analysis and presented as Means6S.E.M. of determinations in five animals of each
group. ***, P,0.001 compared with MI+1st BM-MSCs group. ###, P,0.001 compared with MI group. &&&, P,0.001 compared with sham group.
doi:10.1371/journal.pone.0021005.g004
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Figure 5. Differentiation capacity of donor cells towards cardiomyocytes or neovasculature and vascular endothelial cells in infarct
border zones following the transplantation. Representative micrographs of infarct border zones from sham, MI, MI with the transplantation
with the 1st BM-MSCs (MI+1st BM-MSCs) or with the 5th BM-MSCs (MI+5th BM-MSCs) stained immunofluresence for troponin I (red, left panel) and ß-
gal (green, 2nd panel), with DAPI for nuclei (blue, 3rd panel) and overlap (4th panel). (B) Representative micrographs of infarct border zones stained
immunofluresence for desmin (red, left panel) and ß-gal (green, 2nd panel), with DAPI for nuclei (blue, 3rd panel) and overlap (4th panel). (C)
Representative micrographs of infarct border zones stained immunofluresence for PECAM (red, left panel) and ß-gal (green, 2nd panel), with DAPI for
nuclei (blue, 3rd panel) and overlap (4th panel). (D) Representative micrographs of infarct border zones stained immunofluresence for VEGF (red, left
panel) and ß-gal (green, 2nd panel), with DAPI for nuclei (blue, 3rd panel) and overlap (4th panel). (E) Double positive areas for troponin I and ß-Gal, (F)
Double positive areas for desmin and ß-Gal, (G) Double positive areas for PECAM and ß-Gal, and (H) Double positive areas for VEGF and ß-Gal were
quantitated by computer-assist image analysis and presented as Means6S.E.M. of determinations in five animals of each group. Scale bars in A–D
represent 10 mm. ***, P,0.001 compared with MI+1st MSCs group. ###, P,0.001 compared with MI group.
doi:10.1371/journal.pone.0021005.g005
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the cells with 1,25-(OH)2D3 enhances the formation of CFU-Fs. In
this study, we prepared primary BM-MSCs as seeding cells for the
transplantation using the ‘‘Pour-off’’ culture method. In compar-
ison to the 5th passage BM-MSCs, the 1st BM-MSCs had better
therapeutic effects in the mouse MI model in that they were
readily being engrafted into the scarred myocardium and border
zone, proliferating gradually in situ, forming mature vessels and
cardiomocytes, promoting angiopoiesis, reversing wall thinning in
scarred areas and improving cardiac functions. Those results
indicated that transplantation of the 1st BM-MSCs prepared using
the ‘‘Pour-off’’ culture method has a better therapeutic effect on
acute MI than that of repeated passage BM-MSCs.
b-galactosidase (b-gal) encoded by the bacterial gene lacZ is a
very effective molecular marker to trace the migration, distribu-
tion, proliferation, and differentiation of donor cells in vivo for their
roles in tissue repair following injury. In this study, we used BM-
MSCs derived from b-galactosidase transgenic mice as donor cells
for intramyocardial transplantation in male C57BL/6J wild type
mice following acute MI. We also performed histochemical
staining for LacZ and immunohistochemical staining for b-gal to
show the migration/distribution and differentiation of the donor
cells. Our results indicated that at the 6th week following the
immediate local transplantation of b-gal+ BM-MSCs, b-gal+ cells
were seen at infarct foci, and some of the cells expressed markers
of mature cardiomyocytes. It has been shown that the peak of
inflammatory phase occurs at days 1,3 [27], and survival of
transplanted BM-MSC was likely to be compromised if the cells
were transplanted during this period. It is known that muscular
vasculatures are formed at ,20 days following MI [27]. The
migration of transplanted BM-MSC was likely to be compromised
if the cells were transplanted during this stage. Moreover levels of
some growth factors such as VEGF reach a peak at day 7 following
MI [27], so the best time points for the transplantation of BM-
MSC are likely to be between day 7 and day 14 following MI to
reverse left ventricular remodeling. Although certain therapeutic
effects were demonstrated in this study by immediate transplan-
tation of BM-BMCs, following acute MI, whether transplantation
of BM-MSCs between day 7 and day 14 following MI has a better
therapeutic effect remains to be examined.
Recently, the existence of a population of small embryonic-like
CXCR4-SSEA-Oct4+ stem cells expressing markers for embryonic
stem cells and tissue-committed progenitor cells in adult bone
marrow has been demonstrated [28]. The CXCR4-SSEA-Oct4+
stem cells are self-renewal proliferating cells and play an active role
in tissue repair following MI [29]. This suggests the existence of
very small embryonic-like stem cells (VSELs) in adult bone
marrow. However, the scarcity of CXCR4-SSEA-Oct4+ stem cells
and the lack of an effective amplification method put a limit on its
clinical application. In this study, we found that BM-MSCs in vitro
express markers for embryonic stem cells, cardiac-committed stem
cells, or vascular endothelial-committed stem cells. Gene expres-
sion levels of the stem cell markers by the 1st BM-MSCs are
significantly higher than those expressed by the 5th passage BM-
MSCs, and expressions of some of those markers by the 1st BM-
MSCs are higher than those by total BMCs. This implies
amplification of VSELs in the process of amplifying the 1st BM-
MSCs and differentiation potency towards cardiomyocytes and
vascular endothelial cells. Interestingly Oct4, a key transcription
factor in the induction of somatic cell towards pluripotent stem
cells, is expressed at higher levels in the 1st BM-MSCs, in
comparison to the 5th passage BM-MSCs. PKM2 is known to
upregulate transcription levels of Oct4 [30]. Our results from MS
analysis following 2-DE indicated that the 1st BM-MSCs express
PKM2 at a higher level in comparison to the 5th passage BM-
MSCs. This could be the reason why the 1st BM-MSCs express
higher levels of Oct4. Furthermore, levels of either Csx or GATA-
4 expressed by the 1st BM-MSCs were higher than those by the 5th
passage BM-MSCs. Likewise, in this study, our results indicate
that the differentiation capacities of the 1st BM-MSCs towards
either cardiomyocytes or vascular endothelial cells is superior to
those of the 5th passage BM-MSCs in vivo and in vitro. Undoubtedly
stem cell biological characteristics of donor/seeding cells is a key
factor for improving therapeutic effect of BM-MSCs transplanta-
tion following acute MI.
Recent studies suggest that the transplantation of BM-MSCs
may not only directly induce neovasculature formation but also
enhance indirectly neovasculature formation via autocrine factors
such as VEGF and cytokines [31,32]. It has been shown that the
transplantation of BM-MSCs following MI results in the elevation
of VEGF levels for 2 months [11]. In agreement with those studies,
our results indicate that the transplantation of BM-MSCs
enhances neovasculature formation in MI areas and infarct
border zones. More interestingly, our results from MS analysis
following 2-D electrophoresis indicated that the 1st BM-MSCs
express higher levels of annexin A3, annexin A2, or hn RNP K in
comparison to the 5th passage BM-MSCs. Those three proteins
are known to enhance neovasculature formation via paracrine
mechanisms. Annexin A3, a newly discovered pro-angiogenic
factor, can induce VEGF via the HIF pathway [33]. Annexin A2
can regulate neoangiogenesis in vivo [34], and hn RNP K can
upregulate VEGF mRNA level via stimulating angiotensin II.
Additionally it has been shown that newly regenerated cardiomy-
ocytes are capable of enhancing neovasculature formation via
secreting VEGF [35]. In this study, our results indicate that the 1st
BM-MSCs have greater differentiation potency towards cardio-
myocytes in comparison to the 5th BM-MSCs, therefore it is likely
that the 1st BM-MSCs have more profound pro-angiogenic effect
than the 5th BM-MSCs do. Differences between the 1st BM-MSCs
and the 5th BM-MSCs in the two aspects mentioned above may
explain why more VEGF positive reactions are present in the
infarct areas and border zones in the MI+1st BM-MSCs group
than those in the MI+5th BM-MSCs group.
SDF-1/CXCR4 axis seems particularly important for the
homing, chemotaxis, engraftment, and retention of stem/muscle
progenitor cells within ischemic myocardium. SDF-1 released
from the ischemic myocardium improves cardiac performance
Figure 6. Assessments of cell proliferation and apoptosis in the myocardium following the transplantation of the 1st or the 5th BM-
MSCs into the MI models. Representative micrographs of infarct border zones from sham, MI, MI with the transplantation with the 1st BM-MSCs
(MI+1st BM-MSCs) or with the 5th BM-MSCs (MI+5th BM-MSCs) (A) stained immunohistochemically for PCNA and (B) with TUNEL. Scale bars in A and B
represent 25 mm. (C) PCNA positive cells/field and (D) TUNEL positive cells/field were quantitated by computer-assist image analysis and presented as
Means6S.E.M. of determinations in five animals of each group. (E) Western blots of infarct border area extracts were carried out for expression of Akt,
p-Akt, STAT5, pSTAT5, Pro-caspase3, Activate-caspase3 and b-tubulin was used as a loading control. (F) Akt, (G) p-Akt, (H) STAT5, (I) pSTAT5, (J) Pro-
Caspase3, (K) Activate-caspase3 protein levels relative to b-tubulin protein levels were assessed by densitometric analysis and were presented as
Means6S.E.M. of determinations in five animals of each group. **, P,0.01; ***, P,0.001 compared with MI+1st BM-MSCs group; #, P,0.05; ##,
P,0.01; ###, P,0.001 compared with MI group; &&& P,0.001 compared with sham group.
doi:10.1371/journal.pone.0021005.g006
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through its effects on pro-angiogenesis, cardio-protective, anti-
apoptotic, and wound healing [36]. Moreover, SDF-1 is a potent
chemoattractant for cells expressing CXCR4 [3]. It is evident that
bone marrow and skeletal muscles contain a small population of
cells positive for CXCR4 antigen and expressing genes specific for
early muscle-committed stem/progenitor cells [3]. In this study,
we found that the 1st BM-MSCs expressed CXCR4 at obviously
higher levels in comparison to the 5th passage BM-MSCs,
suggesting that primary BM-MSCs might have more motility in
response to chemoattractants such as SDF-1. Previous studies have
shown that the overexpression of CXCR4 in BM-MSCs has been
correlated to upregulated gene expressions of MMPs, such as
MT1-MMP and MMP-9, under hypoxic conditions [37]. MMPs
are known to play an important role in cell migrations. In this
study, we found that mRNA levels of MMP-2, MMP-9 and MT1-
MMP in the 1st BM-MSCs are higher than those in the 5th BM-
MSCs, and this may be attributable to high levels of CXCR4
levels in the primary BM-MSCs. Meanwhile, our results from MS
analysis following 2-DE indicated that the 1st BM-MSCs express
higher levels of TRAP1, which is known to induce MMP-9
expression in cardiomyocytes [38], in comparison to the 5th
passage BM-MSCs. Previous studies suggest that high levels of
MMPs may contribute to softening the collagenous areas,
enhancing the ability of CXCR4+-MSCs to cross the reconstituted
basement membrane for the generation of new myocytes [37].
Additionally annexin A2, which is highly expressed in the 1st BM-
MSCs and is known to have an effect on fibrinolysis [34], may
have a role in the reorganization of collagen fibril in the MI areas
and border zones. Furthermore, annexin A2 together with Lgals,
another protein highly expressed in the 1st BM-MSCs, may both
regulate the adhesion, homing, migration, and engraftment of
BM-MSCs following the transplantation.
In this study, our data of immunohistochemical staining for PCNA
showed that a number of PCNA-positive cells in MI areas and infarct
border zones in the MI+1st BM-MSCs group was significantly greater
than that in the MI+5th BM-MSCs group in MI areas and border
zones. This indicates a strong amplification potential of the primary
BM-MSCs in vivo. Relevantly our data of MS analysis following 2-DE,
showed mcm7, a cell proliferation-promoting protein [39], is highly
expressed by the 1st BM-MSCs. In contrast, the isoform 2 of src kinase-
associated phosphoprotein, a cell proliferation-inhibiting protein [40],
is upregulated in the 5th passage BM-MSCs.
In this study, we found that, in comparison to the transplan-
tation of the 5th BM-MSCs, the transplantation of the 1st BM-
MSCs has more evident anti-apopotsis effect in MI areas and
border zones. Multiple mechanisms may underlie this difference.
First of all, as shown by MS analysis following 2-DE, lgals, a
protein known to have anti-apoptotic effect through enhancing p-
AKT levels [41], is highly expressed in the primary BM-MSCs. p-
Akt may contribute to the protection of ischemic myocardium,
possibly through enhanced expression of VEGF, as well as by
decreasing ROS [10]. Secondly, as identified by MS analysis
following 2-DE, trap1, a protein known to have an important role
in anti-apoptosis through suppressing the formation of ROS [41],
is highly expressed in the 1st BM-MSCs. Meanwhile, as identified
by MS analysis following 2-DE, catalase and stip1 are highly
expressed in the 1st BM-MSCs, and these two proteins may rescues
cells from apoptosis by protecting cells against oxidative stress by
H2O2 [42,43]. Furthermore, efhd2, a protein known to contribute
to BCR-induced apoptosis by enhancing BCR signal [44], is
highly expressed in the 5th BM-MSCs. Ultimately, as shown by
our immunoblotting results, levels of either total caspase3 or its
active form, which play a critical role in the execution of apoptosis,
is down-regulated in the 1st BM-MSCs transplanted heart more
obviously than the 5th BM-MSCs transplanted heart. This implies
anti-apoptotic property of the 1st BM-MSCs is superior to that of
the 5th BM-MSCs. Our TUNEL assay results support this
possibility. Additionally, p-STAT5 level in lysate samples prepared
from primary BM-MSCs transplanted hearts was higher than that
in those prepared from the 5th BM-MSCs transplanted hearts,
raising the possibility that the activation of the STAT5 pathway
may inhibit caspase-3-mediated apoptosis in the primary BM-
MSCs. To sum up, in comparison to the transplantation of the 5th
passage BM-MSCs, the transplantation of the 1st BM-MSCs more
effectively leads to the efficient activation of Akt/STAT5 pathway.
This inhibits caspase-3-mediated apoptosis and efficient inhibition
of ROS formation, which protects cardiomyocytes from ischemic
injury resulted from oxidative stress. It may also play a better role
in preventing post-MI ventricular remodeling, through assisting
viable ventricular cardiomyocytes to escape from the immune
reaction induced by BCR, and /or alleviating inflammation in the
MI areas and border zones.
In summary, in the present study, a novel ‘‘Pour-off’’ method was
used to obtain sufficient numbers of 1st BM-MSCs with a good stem
cell quality. Following intramyocardial transplantion into the mouse
MI model, in comparison to the 5th BM-MSCs, the 1st BM-MSCs
were more capable of rapidly migrating, proliferating in situ, and
differentiating into mature vascular endothelial cells and cardiomy-
ocytes. Meanwhile, undifferentiated 1st BM-MSCs may contribute to
the infarct-healing process and to improving post-MI cardiac
performance through its paracrine effects on promoting cell
migration, homing, and proliferation and neovasculature formation,
and preventing apoptosis in the MI areas and border zones.
Therefore, using the 1st BM-MSCs obtained using the ‘‘Pour-off’’
method as seeding cells for intramyocardial transplantation following
acute MI in mice has a better therapeutic effect than using the 5th
BM-MSCs obtained from conventional repeated passaging.
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Figure 7. Assessment cardiac functions following the transplantation of the 1st or the 5th BM-MSCs into MI models. (A) Representative
graphs of ventricles from sham, MI, MI with the transplantation with the 1st BM-MSCs (MI+1st BM-MSCs) or with the 5th BM-MSCs (MI+5th BM-MSCs)
stained histochemically for total collagen. Scale bar represent 800 mm. (B) Infarct wall thickness and (C) total collagen positive areas were quantitated
by computer-assist image analysis and presented as Means6S.E.M. of determinations in five animals of each group. (D) Representative
echocardiographs recorded after 1 and 6 weeks following the transplantation. (E) LVIDd, (F) LVIDs, (G) LVFS, (H) LVEDV, (I) LVESV and (J) LVEF. Each
value is the means 6 SEM of determinations in 5 animals of each group. **, P,0.01; ***, P,0.001 compared with MI+1st BM-MSCs group. ##,
P,0.01; ###, P,0.001 compared with MI group. &&&, P,0.001 compared with sham group.
doi:10.1371/journal.pone.0021005.g007
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